Revolution Medicines’ Daraxonrasib Receives Positive EU CHMP Opinion
The European Medicines Agency’s CHMP recommended marketing authorization for daraxonrasib in the European Union for metastatic pancreatic cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Revolution Medicines’ daraxonrasib wins positive EU CHMP opinion
The CHMP recommended marketing authorization in the European Union for metastatic pancreatic cancer.